| Dr Joel R Okazaki, MD | |
|
912141 Fort Weaver Rd, Ewa Beach, HI 96706 | |
| (808) 678-7037 | |
| (808) 678-7039 |
| Full Name | Dr Joel R Okazaki |
|---|---|
| Gender | Male |
| Speciality | Radiology - Diagnostic Radiology |
| Location | 912141 Fort Weaver Rd, Ewa Beach, Hawaii |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1235119850 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2085R0202X | Radiology - Diagnostic Radiology | MD5551 (Hawaii) | Primary |
| Entity Name | Kahuku Medical Center |
|---|---|
| Entity Type | Part A Provider - Critical Access Hospital |
| Entity Identifiers | NPI Number: 1245430065 PECOS PAC ID: 1557446697 Enrollment ID: O20080312000783 |
News Archive
Relying on abstinence-only sex education as the "primary tool to reduce teenage pregnancies" and sexually transmitted infections, as "favored by the Bush administration and conservatives in Congress, looks increasingly foolish and indefensible," a New York Times editorial says.
AlphaCore Pharma, a biopharmaceutical company developing ACP-501 (rhLCAT) for the treatment of high risk atherosclerosis and serious lipid metabolism disorders, today announced the initiation of a Phase 1 study of ACP-501 in patients with stable coronary arterial disease.
The benefits of hydroxyurea treatment in people with sickle cell disease are well known - fewer painful episodes, fewer blood transfusions and fewer hospitalizations. Now new research from the Johns Hopkins Children's Center and other institutions reveals that by preventing such complications, the drug can also considerably lower the overall cost of medical care in children with this condition.
Elusys Therapeutics, Inc., a biopharmaceutical company developing antibody therapies to treat infectious disease, today announced it has completed three phase 3 healthy adult volunteer safety studies of obiltoxaximab (ETI-204).
Three people have now have reported a dramatic improvement in vision after having gene therapy in both eyes after having lost their eyesight as children.
› Verified 7 days ago
| Entity Name | Gaas, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1013267301 PECOS PAC ID: 2466603329 Enrollment ID: O20121127000443 |
News Archive
Relying on abstinence-only sex education as the "primary tool to reduce teenage pregnancies" and sexually transmitted infections, as "favored by the Bush administration and conservatives in Congress, looks increasingly foolish and indefensible," a New York Times editorial says.
AlphaCore Pharma, a biopharmaceutical company developing ACP-501 (rhLCAT) for the treatment of high risk atherosclerosis and serious lipid metabolism disorders, today announced the initiation of a Phase 1 study of ACP-501 in patients with stable coronary arterial disease.
The benefits of hydroxyurea treatment in people with sickle cell disease are well known - fewer painful episodes, fewer blood transfusions and fewer hospitalizations. Now new research from the Johns Hopkins Children's Center and other institutions reveals that by preventing such complications, the drug can also considerably lower the overall cost of medical care in children with this condition.
Elusys Therapeutics, Inc., a biopharmaceutical company developing antibody therapies to treat infectious disease, today announced it has completed three phase 3 healthy adult volunteer safety studies of obiltoxaximab (ETI-204).
Three people have now have reported a dramatic improvement in vision after having gene therapy in both eyes after having lost their eyesight as children.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Joel R Okazaki, MD 941 Kamehameha Hwy, Ste 208, Pearl City, HI 96782-2516 Ph: (808) 454-5200 | Dr Joel R Okazaki, MD 912141 Fort Weaver Rd, Ewa Beach, HI 96706 Ph: (808) 678-7037 |
News Archive
Relying on abstinence-only sex education as the "primary tool to reduce teenage pregnancies" and sexually transmitted infections, as "favored by the Bush administration and conservatives in Congress, looks increasingly foolish and indefensible," a New York Times editorial says.
AlphaCore Pharma, a biopharmaceutical company developing ACP-501 (rhLCAT) for the treatment of high risk atherosclerosis and serious lipid metabolism disorders, today announced the initiation of a Phase 1 study of ACP-501 in patients with stable coronary arterial disease.
The benefits of hydroxyurea treatment in people with sickle cell disease are well known - fewer painful episodes, fewer blood transfusions and fewer hospitalizations. Now new research from the Johns Hopkins Children's Center and other institutions reveals that by preventing such complications, the drug can also considerably lower the overall cost of medical care in children with this condition.
Elusys Therapeutics, Inc., a biopharmaceutical company developing antibody therapies to treat infectious disease, today announced it has completed three phase 3 healthy adult volunteer safety studies of obiltoxaximab (ETI-204).
Three people have now have reported a dramatic improvement in vision after having gene therapy in both eyes after having lost their eyesight as children.
› Verified 7 days ago